



Shanghai, China

Flexible, fully disposable GMP facility

History: Member of the global network since 2014.

Employees: more than 200

Technology:

- Mammalian Cell Culture
- Single Use Bioreactors

Capabilities:

- Upstream and downstream process optimization
- Clinical and commercial supply
- Fill & Finish

Key characteristics:

- Monoclonal antibodies and fusion proteins
- cGMP facilities are certified by the National Medical Products Administration of China (NMPA, formerly known as CFDA: China Food and Drug Administration)
- Our operations and quality systems meet the cGMP requirements of international regulatory authorities
- Providing first-class biopharmaceutical medicines to China and to the global market

We deliver progress –
and it's our pleasure.

Boehringer Ingelheim BioXcellence™ welcomes
your inquiries, questions and feedback.

www.bioxcellence.com
bioxcellence@boehringer-ingelheim.com

Discover Boehringer Ingelheims'
global career opportunities:
www.careers.boehringer-ingelheim.com

June 2020

Boehringer Ingelheim BioXcellence™

Wherever you are,
we are by your side.



 **Boehringer
Ingelheim**



Biberach, Germany

Flagship site for large scale and commercial manufacturing in cell culture

History: Boehringer Ingelheim's first mammalian cell culture facility started in 1983 and became the largest in Europe.

Employees: more than 2,500

Technology:

- Mammalian Cell Culture
- Stainless Steel and Single-Use Bioreactors

Capabilities:

- Center of excellence in cell line and process development
- Clinical and commercial supply
- Fill & Finish

Key characteristics:

- Launch site for almost all of our customers commercial mammalian products
- Monoclonal antibodies, fusion proteins, antibody fragments, complex antibodies, enzymes and other recombinant proteins
- 60 different biopharmaceuticals and about 80 different processes for manufacturing pre-clinical and clinical material



Vienna, Austria

Specialists for microbial fermentation

History: The microbial fermentation facility was built in 1983 and expanded in 2005; Groundbreaking for mammalian cell culture facility was in 2017.

Employees: more than 1,200

Technology:

- Microbial technologies
- Mammalian Cell Culture to be in place 2021
- Stainless Steel and Single-Use Bioreactors

Capabilities:

- Cell line and process development
- Clinical and commercial supply
- Fill & Finish

Key characteristics:

- Several independent fermentation facilities for *E.coli* and other bacteria as well as for yeast technologies
- Non-glycosylated recombinant proteins, antibody fragments, protein scaffolds, and plasmid DNA (pDNA)
- Fill & Finish of lyophilized and liquid drug product in vials for clinical supply



Fremont, CA, USA

Mammalian Cell Culture Centre in the heart of Silicon Valley

History: Member of the global network since 2011, the site was further expanded in 2018.

Employees: more than 600

Technology:

- Mammalian Cell Culture
- Stainless Steel and Single-Use Bioreactors
- Fed batch, perfusion and fully continuous manufacturing

Capabilities:

- Process development
- Clinical and commercial supply
- Fill & Finish

Key characteristics:

- Monoclonal antibodies, fusion proteins, antibody fragments, complex antibodies, enzymes and other recombinant proteins
- Two identical, independent trains for Cell Culture and purification in 2 kL or 15 kL bioreactors
- Facility design based on extensive use of glass windows providing visibility into the manufacturing areas